Information Provided By:
Fly News Breaks for May 13, 2019
ICPT
May 13, 2019 | 08:05 EDT
Wedbush analyst Liana Moussatos lowered her price target for Intercept to $243 from $251 following quarterly results and an update on the REVERSE trial of Ocaliva for the treatment of NASH cirrhosis. The analyst projects runway to cash flow positivity in Q1 of 2021, reiterates an Outperform rating on the shares and views recent weakness in the stock as a buying opportunity.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.